AbbVie and ADARx to develop siRNA therapeutics for multiple disease areas
AbbVie and ADARx Pharmaceuticals have announced a partnership and licence option deal for developing small interfering ribonucleic acid (siRNA) therapeutics targeting various disease areas such as immunology, oncology, and neuroscience.